Welcome to our dedicated page for PTNTD SEC filings (Ticker: PTNTD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTNTD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTNTD's regulatory disclosures and financial reporting.
Palatin Technologies (PTNT): Logos Global Management and affiliated entities filed a Schedule 13G reporting beneficial ownership of 142,292 shares of Common Stock, representing 9.9% of the class. The reporting persons have 0 sole voting/dispositive power and 142,292 shared voting/dispositive power.
The filing lists Logos Global Management LP, Logos Global Management GP LLC, Logos Opportunities Fund IV LP and GP, Arsani William, and Graham Walmsley as reporting persons. The percentage is calculated based on 140,000 shares and warrants to acquire 224,000 shares, and 1,422,060 shares outstanding following the issuer’s offering on November 6, 2025. They certify the holdings are in the ordinary course and not to influence control.
Palatin Technologies Inc. received a Schedule 13G showing that Point72 entities and Steven A. Cohen reported beneficial ownership of 2,307,000 shares of Common Stock, representing 9.9% of the class as of November 12, 2025. The position includes 2,192,000 shares issuable upon exercise of warrants, with certain warrants subject to a 9.99% blocker that limits exercises that would push ownership above that threshold.
The reporting persons list shared voting and dispositive power over 2,307,000 shares and no sole voting or dispositive power. Point72 Asset Management, L.P. manages the securities held by Point72 Associates, with Point72 Capital Advisors, Inc. as its general partner, and Mr. Cohen controlling both entities. The certification states the securities were not acquired for the purpose of changing or influencing control, consistent with a passive Schedule 13G filing.
Palatin Technologies reported that underwriters exercised their over-allotment option tied to its recent public offering. The underwriters purchased 280,615 common shares at $6.50, plus pre-funded warrants for 84,000 shares at $6.50, and the company issued accompanying Series J warrants to buy up to 364,615 shares at $6.50 and Series K warrants to buy up to 364,615 shares at $8.125. This added approximately $2.37 million in gross proceeds, before fees and expenses.
After giving effect to the over-allotment exercise, total gross proceeds from the offering rose to approximately $18.2 million. Palatin also filed a legal opinion covering the securities and noted a related press release.
Palatin Technologies (PTNT) entered an underwriting agreement for a public offering of 2,430,769 shares of common stock (or pre-funded warrants in lieu) together with Series J and Series K warrants at a combined public offering price of $6.50 per share and accompanying warrants. The company expects gross proceeds of approximately $15.8 million, with a 45-day option for up to 364,615 additional shares. Closing is expected on or about November 12, 2025, subject to the resumption of trading on NYSE American.
Series J Warrants have a $6.50 exercise price and an expiry tied to the earlier of 18 months or 31 days after FDA acceptance of an IND for an in-house obesity treatment compound. Series K Warrants have an $8.125 exercise price and a five-year term, subject to early termination if Series J conditions aren’t met before the FDA exercise period ends. The company noted a prior 1-for-50 reverse split and submitted pro forma materials supporting compliance with the NYSE American $6.0 million stockholders’ equity standard, citing $8.8 revenue from a Boehringer Ingelheim collaboration and expected $14.7 million net proceeds. Trading is expected to resume on NYSE American under PTN on November 12, 2025.
Palatin Technologies, Inc. filed Amendment No. 2 to a Form S-1 for a firm-commitment public offering of 2,307,692 shares of common stock, each sold with a Series J warrant to purchase one share and a Series K warrant to purchase one share. The filing also registers an alternative of up to 2,307,692 pre-funded warrants in lieu of shares, 46,153 underwriter warrants, and the shares underlying all such warrants.
The expected combined offering price range is $6.00–$7.00 (assumed $6.50 midpoint). Underwriting discounts are 7.0%, with a 45‑day over‑allotment option for up to 346,153 additional shares and accompanying warrants. Estimated net proceeds are approximately $13.9 million at the assumed price, intended for working capital and development of MC4R obesity programs. Closing is conditioned on re‑listing the common stock on NYSE American.
Holders unable to exceed ownership caps may elect pre‑funded warrants with a $0.0001 exercise price, subject to 4.99% (or 9.99%) beneficial ownership limits. Shares outstanding were 973,291 as of October 16, 2025.
Palatin Technologies, Inc. reported a net loss of $17.3 million for the year ended June 30, 2025 and management concluded there is substantial doubt about the company’s ability to continue as a going concern. The company sold its Vyleesi product assets and recorded an upfront payment of $9.5 million plus additional consideration, recognizing a $3.13 million gain on the sale and a $2.1179 million gain on eliminated purchase commitments for the fiscal year. Cash and short-term money market deposits included $2,286,603 in money market accounts at June 30, 2025 (compared with $9,089,113 at June 30, 2024). Current liabilities totaled $8,010,030 and certain current assets or balances referenced include $2,564,265. The company continues clinical development across multiple melanocortin receptor (MCR) programs, noting positive topline results reported in 2024–2025 for several programs and projected IND filings for two obesity-focused programs in early 2026. Palatin disclosed extensive financing instruments that may dilute existing shareholders, including convertible preferred stock, options, restricted stock units, and multiple series of warrants outstanding or issuable.
